|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.51 CNY | +1.84% |
|
+5.79% | +61.87% |
| 11:01pm | SKB Biopharma Gets China Nod for Advanced Solid Tumors Drug Trial | MT |
| 17/07 | Sichuan Kelun Pharmaceutical Receives AAA Rating from China's Lianhe Credit; Shares Slide 10% | MT |
| Market Cap | 75.56B 11.16B 9.81B 9.13B 8.39B 15.75B 1,070B 15.95B 109B 42.39B 528B 41.89B 40.98B 1,826B | P/E 2026 * |
39.1x | P/E 2027 * | 30.6x |
|---|---|---|---|---|---|
| Enterprise Value | 68.74B 10.15B 8.92B 8.31B 7.63B 14.33B 974B 14.51B 98.74B 38.57B 481B 38.11B 37.29B 1,661B | EV / Sales 2026 * |
3.49x | EV / Sales 2027 * | 3.09x |
| Free-Float |
67.76% | Yield 2026 * |
1.19% | Yield 2027 * | 1.55% |
Last Transcript: Sichuan Kelun Pharmaceutical Co., Ltd.
| 1 day | +1.84% | ||
| 1 week | +5.79% | ||
| Current month | +23.34% | ||
| 1 month | +33.46% | ||
| 3 months | +40.02% | ||
| 6 months | +48.01% | ||
| Current year | +61.87% |
| 1 week | 44.96 |  | 51.35 |
| 1 month | 35.88 | | 52.78 |
| Current year | 29.07 | | 52.78 |
| 1 year | 28.14 | | 52.78 |
| 3 years | 21.6 | | 52.78 |
| 5 years | 14.53 | | 52.78 |
| 10 years | 14.53 | | 52.78 |
| Manager | Title | Age | Since |
|---|---|---|---|
Si Chuan Liu
CEO | Chief Executive Officer | 42 | 08/09/2015 |
De Gui Lai
DFI | Director of Finance/CFO | 55 | 23/10/2014 |
Meng Ran Wang
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
CHM | Chairman | 75 | 01/01/1996 |
Fu Qing Wang
BRD | Director/Board Member | 63 | 15/05/2024 |
Si Chuan Liu
BRD | Director/Board Member | 42 | 26/06/2009 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/2/23 | Buy | Public Communications Manager | 37,000 | 0.0033% | ||
| 2/2/23 | Buy | Chief Financial Officer | 37,000 | 0.0033% | ||
| 15/7/22 | Buy | Chief Financial Officer | 15,000 | 0.0013% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.84% | +5.79% | +35.09% | +63.94% | 10.96B | |
| +0.34% | +4.37% | +48.12% | +163.08% | 1,067B | |
| +1.94% | +7.62% | +61.09% | +54.17% | 635B | |
| -0.05% | +1.91% | +36.97% | +73.48% | 458B | |
| +1.41% | +8.56% | +38.18% | +32.17% | 347B | |
| +1.28% | +4.40% | +37.69% | +41.62% | 295B | |
| +1.72% | +4.10% | +19.44% | +20.45% | 262B | |
| +1.84% | -0.46% | -27.63% | -38.65% | 216B | |
| +0.53% | +3.53% | +25.14% | +59.73% | 203B | |
| +1.80% | -1.46% | +16.14% | +71.57% | 161B | |
| Average | +1.42% | +1.23% | +29.02% | +54.16% | 365.45B | |
| Weighted average by Cap. | +1.15% | +1.95% | +37.94% | +78.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 19.69B 2.91B 2.56B 2.38B 2.19B 4.1B 279B 4.16B 28.29B 11.05B 138B 10.92B 10.68B 476B | 22.02B 3.25B 2.86B 2.66B 2.44B 4.59B 312B 4.65B 31.63B 12.35B 154B 12.21B 11.94B 532B |
| Net income | 1.94B 286M 252M 234M 215M 404M 27.46B 409M 2.78B 1.09B 13.56B 1.07B 1.05B 46.86B | 2.53B 374M 329M 306M 281M 528M 35.9B 535M 3.64B 1.42B 17.73B 1.41B 1.37B 61.26B |
| Net Debt | -6.82B -1.01B -885M -824M -757M -1.42B -96.54B -1.44B -9.79B -3.82B -47.67B -3.78B -3.7B -165B | -7.55B -1.11B -980M -912M -838M -1.57B -107B -1.59B -10.84B -4.23B -52.78B -4.18B -4.09B -182B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/07/26 | CNY 47.51 | +1.84% | 39,607,220 |
| 24/07/26 | CNY 46.65 | -9.15% | 54,237,490 |
| 23/07/26 | CNY 51.35 | +4.33% | 48,619,078 |
| 22/07/26 | CNY 49.22 | +3.93% | 47,244,657 |
| 21/07/26 | CNY 47.36 | -0.92% | 46,423,783 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 002422 Stock
Select your edition
All financial news and data tailored to specific country editions
